Last quarter (Q ), OWC Pharmaceutical Research's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, OWC Pharmaceutical Research's net income was $-1.05M. See OWC Pharmaceutical Research’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 18	Dec 17	Dec 16	Dec 15	Dec 14
Total Revenue	-	$ 0.00	$ 0.00	$ 50.00K	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-	$ 0.00
Operating Expense	$ 3.77M	$ 4.30M	$ 4.55M	$ 2.15M	$ 1.65M	$ 5.03M
Operating Income	$ -3.77M	$ -4.30M	$ -4.55M	$ -2.10M	$ -1.65M	$ -5.03M
Net Non Operating Interest Income Expense	$ -9.00K	$ -826.00K	$ -5.00K	$ -189.25K	$ -3.56K	$ -3.09K
Other Income Expense	$ 5.12M	$ -5.14M	-	-	$ -3.07K	$ -34.03K
Pretax Income	$ 1.34M	$ -10.26M	$ -4.56M	$ -2.29M	$ -1.65M	$ -5.07M
Tax Provision	-	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.29M	$ -12.71M	$ -4.56M	$ -2.29M	$ -1.65M	$ -5.07M
Basic EPS	$ -0.02	$ -0.09	$ -0.03	$ -0.02	$ -0.02	$ -0.10
Diluted EPS	$ -0.07	$ -0.09	$ -0.03	$ -0.02	$ -0.02	$ -0.10
Basic Average Shares	$ 738.08M	$ 148.07M	$ 145.20M	$ 96.36M	$ 80.59M	$ 52.21M
Diluted Average Shares	$ 746.06M	$ 148.07M	$ 145.20M	$ 96.36M	$ 80.59M	$ 52.21M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 3.77M	$ 4.30M	$ 4.55M	$ 2.15M	$ 1.65M	$ 5.03M
Net Income From Continuing And Discontinued Operation	$ 1.34M	$ -10.26M	$ -4.56M	$ -2.29M	$ -1.65M	$ -5.07M
Normalized Income	$ -1.84M	$ -5.12M	$ -4.56M	$ -2.29M	$ -1.65M	$ -5.04M
Interest Expense	-	$ 3.00K	$ 5.00K	-	$ 491.00	$ 3.19K
EBIT	$ -9.73M	$ -10.26M	$ -4.55M	$ -2.10M	$ -1.65M	$ -5.07M
EBITDA	$ -9.72M	$ -10.25M	$ -4.55M	$ -2.09M	$ -1.64M	$ -5.06M

Currency in USD

OWC Pharmaceutical Research Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing